The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Open accessAbstract
BACKGROUND: Type 2 (non-insulin-dependent) diabetes is associated with a marked increase in the risk of coronary heart disease. It has been debated whether patients with diabetes who have not had myocardial infarctions should be treated as aggressively for cardiovascular risk factors as patients who have had myocardial infarctions. METHODS: To address this issue, we compared the seven-year incidence of myocardial infarction (fatal and nonfatal) among 1373 nondiabetic subjects with the incidence among 1059 diabetic subjects, all from a Finnish population-based study. RESULTS: The seven-year incidence rates of myocardial infarction in nondiabetic subjects with and without prior myocardial infarction at base line were 18.8 percent and 3.5 percent, respectively (P<0.001). The seven-year incidence rates of myocardial infarction in diabetic subjects with and without prior myocardial infarction at base line were 45.0 percent and 20.2 percent, respectively (P<0.001). The hazard ratio for death from coronary heart disease for diabetic subjects without prior myocardial infarction as compared with nondiabetic subjects with prior myocardial infarction was not significantly different from 1.0 (hazard ratio, 1.4; 95 percent confidence interval, 0.7 to 2.6) after adjustment for age and sex, suggesting similar risks of infarction in the two groups. After further adjustment for total cholesterol, hypertension, and smoking, this hazard ratio remained close to 1.0 (hazard ratio, 1.2; 95 percent confidence interval, 0.6 to 2.4). CONCLUSIONS: Our data suggest that diabetic patients without previous myocardial infarction have as high a risk of myocardial infarction as nondiabetic patients with previous myocardial infarction. These data provide a rationale for treating cardiovascular risk factors in diabetic patients as aggressively as in nondiabetic patients with prior myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“diabetes-related morbidity and mortality is primarily due to cardiovascular complications [17,18,19].”
From Recent Experimental Studies of Maternal Obesity, Diabetes during Pregnancy and the Developmental Origins of Cardiovascular Disease (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Patients with type 2 diabetes mellitus have an increased incidence of atherosclerotic cardiovascular disease.1–4”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, T2DM is associated with low-grade inflammation,382, 383 cardiovascular disease,384, 385 nephropathy386, 387 and alterations in the secretion of various hormones, including IL-6, IL-18, tumor necrosis factor-α,388 adiponectin and leptin,389 neuropeptides,390 ghrelin391, 392 and the incretins GLP-1 and GIP.219, 220, 221, 222, 223”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [384]
In the citing paper
“In contrast, patients who did not have T2DM, the death rates due to cardiovascular causes were 2.1 and 15.9%, respectively.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [6]
In the citing paper
“Furthermore, people with T2DM are disproportionately affected by CVD compared with non-diabetic subjects [6].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [6]
In the citing paper
“In persons with T2DM, the death rates were 15.4% for those with no prior myocardial infarction (MI) and 42.0% in patients having a history of MI.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [6]
In the citing paper
“It has been stated that type 2 diabetic patients without a previous history of myocardial infarction have the same risk of coronary artery disease (CAD) as non-diabetic subjects with a history of myocardial infarction [69].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Self-citationDiabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
Kannel, W. B., & McGee, D. L. (1979) · Diabetes Care · doi:10.2337/diacare.2.2.120 · Cited by 1,203
Diabetes and atherosclerosis: An epidemiologic view
Pyörälà, K., Laakso, M., & Uusitupa, M. I. J. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 912
Self-citationPekkanen, J., Linn, S., Heiss, G., Suchindran, C. M., Leon, A., Rifkind, B. M., & Tyroler, H. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222403 · Cited by 821
Research works printed but not linked: 5
- 1993, JAMA, 209, 3015
- 1994, Lancet, 344, 1383
- 1985, WHO Tech Rep Ser, 727, 1
- Walker AE, 1981, Stroke, 12, I
- D'Agostino RB Jr, Mykkänen L, Goff D, et al. Atherosclerosis in type 2 diabetic and non-diabetic subjects with and without previous myocardial infarction: the Insulin Resistance Atherosclerosis Study (IRAS). Presented at the American Heart Association 38th Annual Conference on Cardiovascular Disease: Epidemiology and Prevention, Santa Fe, N.M., March 18–21, 1998. abstract.
Cited by
Sorted by citations
Items 201–229 of 229
Bahceci, M., Tuzcu, A., Ogun, C., Canoruc, N., Iltimur, K., & Aslan, C. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345357 · Cited by 53
van Werkhoven, J. M., Gaemperli, O., Schuijf, J. D., Jukema, J. W., Kroft, L. J., Leschka, S., Alkadhi, H., Valenta, I., Pundziute, G., de Roos, A., et al. (2009) · Heart · doi:10.1136/hrt.2009.167353 · Cited by 52
Genest, J., Frohlich, J., & Steiner, G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.12.022 · Cited by 51
Olesen, K. K. W., Madsen, M., Egholm, G., Thim, T., Jensen, L. O., Raungaard, B., Bøtker, H. E., Sørensen, H. T., & Maeng, M. (2017) · Diabetes Care · doi:10.2337/dc16-2388 · Cited by 51
Rahman, F., McEvoy, J. W., Ohkuma, T., Marre, M., Hamet, P., Harrap, S., Mancia, G., Rodgers, A., Selvin, E., Williams, B., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12414 · Cited by 48
Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44
Aggarwal, B., Shah, G. K., Randhawa, M., Ellis, S. G., Lincoff, A. M., & Menon, V. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.11.060 · Cited by 43
Sun, C., Fan, S., Wang, X., Lu, J., Zhang, Z., Wu, D., Shan, Q., & Zheng, Y. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.04.012 · Cited by 43
Mourad, J.-J., & Le Jeune, S. (2008) · Journal of Hypertension · doi:10.1097/01.hjh.0000334072.97080.33 · Cited by 41
Cardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents
Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00006 · Cited by 38
Nakajima, K., Yamasaki, Y., Kusuoka, H., Izumi, T., Kashiwagi, A., Kawamori, R., Shimamoto, K., Yamada, N., & Nishimura, T. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1207-9 · Cited by 36
Kereliuk, S. M., & Dolinsky, V. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084467 · Cited by 34
Taggart, D. P., Audisio, K., Gerry, S., Robinson, N. B., Rahouma, M., Soletti, G. J., Cancelli, G., Benedetto, U., Lees, B., Gray, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac199 · Cited by 33
Chue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
van den Hoogen, I. J., van Rosendael, A. R., Lin, F. Y., Lu, Y., Dimitriu-Leen, A. C., Smit, J. M., Scholte, A. J. H. A., Achenbach, S., Al-Mallah, M. H., Andreini, D., et al. (2020) · Journal of Cardiovascular Computed Tomography · doi:10.1016/j.jcct.2019.11.015 · Cited by 31
Schindhelm, R. K., Alssema, M., Scheffer, P. G., Diamant, M., Dekker, J. M., Barto, R., Nijpels, G., Kostense, P. J., Heine, R. J., Schalkwijk, C. G., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2585 · Cited by 30
Prescription omega-3 fatty acid products: Considerations for patients with diabetes mellitus
Avallone, L., Shaikh, A., Hassan, A., & Tajuddin, N. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s97036 · Cited by 22
Ansari, P., Khan, J. T., Choudhary, S., Reberio, A. D., Kumar, S., Seidel, V., Abdel-Wahab, Y. H. A., & Flatt, P. R. (2024) · doi:10.20944/preprints202408.1739.v1 · Cited by 89
Loncar, G., Barthelemy, O., Berman, E., Kerneis, M., Petroni, T., Payot, L., Choussat, R., Silvain, J., Collet, J.-P., Helft, G., et al. (2015) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2015.06.001 · Cited by 17
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17
van Baar, H., Hulshof, P. J. M., Tieland, M., & de Groot, C. P. G. M. (2015) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2015.05.002 · Cited by 15
Liu, Z., Xu, Y., Hao, H., Yin, C., Xu, J., Li, J., Wang, Y., & Xu, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.140 · Cited by 16
Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus
Levy, P. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0087 · Cited by 15
Heart rate dynamics after exercise in cardiac patients with and without type 2 diabetes
Neves, V. (2011) · Frontiers in Physiology · doi:10.3389/fphys.2011.00057 · Cited by 14
Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors
Turchin, A., Petito, L. C., Hegermiller, E., Carnahan, R., DeVries, A., Goel, S., Lansang, M. C., McDonnell, M. E., Nair, V., Priest, E., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.23067 · Cited by 14
Gimeno Orna, J. A., Boned Juliani, B., Lou Arnal, L. M., & Castro Alonso, F. J. (2003) · Revista Clínica Española · doi:10.1016/s0014-2565(03)71346-0 · Cited by 13
Kim, Y., Park, S., Kim, M.-H., Song, S. H., Lee, W. M., Kim, H. S., Jin, K., Han, S., Kim, Y. C., Han, S. S., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227694 · Cited by 12
Shen, M., Xie, Q., Zhang, R., Yu, C., & Xiao, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1175021 · Cited by 11
Sugur, K., Kempegowda, S. N., Shambu, S. K., Mahadevappa, M., Kengegowda, V. K., Gowda, J., & Thimmulappa, R. K. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103143 · Cited by 4
Metadata
- Authors
- Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- University of Eastern Finland (FI)
- University of Turku (FI)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-07-23
- Volume
- 339
- Issue
- 4
- Pages
- 229-234
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2331274940
- Cited by
- 7,000
- References
- 23
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 103 · 2023: 145 · 2022: 152 · 2021: 190 · 2020: 217 · 2019: 255 · 2018: 195 · 2017: 262 · 2016: 232 · 2015: 295 · 2014: 289 · 2013: 337 · 2012: 367
- FWCI
- 88.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, coronary heart disease mortality, myocardial infarction incidence, cardiovascular risk factors, cardiovascular risk stratification, old myocardial infarction, total cholesterol, hypertension, smoking, diabetes and cardiovascular risk
- MeSH terms
- Coronary Disease, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Female, Finland, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Risk Factors, Incidence, Proportional Hazards Models, Survival Analysis, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
